PIK3CA and lung cancer: EGFR mutant lung cancers with genetic alterations that activate the PI3K-AKT signaling pathway or IGF1R signaling may benefit from treatment with PI3K or AKT inhibitors or an IGF1R antibody, respectively, in combination with an EGFR TKI (Figure 1).